Literature DB >> 9691909

What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?

S A Riley1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9691909      PMCID： PMC1727139          DOI： 10.1136/gut.42.6.761

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  35 in total

1.  CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.

Authors:  A P DICK; M J GRAYSON; R G CARPENTER; A PETRIE
Journal:  Gut       Date:  1964-10       Impact factor: 23.059

2.  Sulphasalazine and salicylazosulphadimidine in ulcerative colitis.

Authors:  J H BARON; A M CONNELL; J E LENNARD-JONES; F A JONES
Journal:  Lancet       Date:  1962-05-26       Impact factor: 79.321

3.  A critical analysis of the use of salicylazosulfapyridine in chronic ulcerative colitis.

Authors:  C G MOERTEL; J A BARGEN
Journal:  Ann Intern Med       Date:  1959-11       Impact factor: 25.391

4.  A defence of the small clinical trial: evaluation of three gastroenterological studies.

Authors:  J Powell-Tuck; K D MacRae; M J Healy; J E Lennard-Jones; R A Parkins
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-01

5.  Nephrotic syndrome after treatment with 5-aminosalicylic acid.

Authors:  B H Novis; Z Korzets; P Chen; J Bernheim
Journal:  Br Med J (Clin Res Ed)       Date:  1988-05-21

6.  A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis.

Authors:  M Safdi; M DeMicco; C Sninsky; P Banks; L Wruble; J Deren; G Koval; T Nichols; S Targan; C Fleishman; B Wiita
Journal:  Am J Gastroenterol       Date:  1997-10       Impact factor: 10.864

7.  Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis.

Authors:  J K Marshall; E J Irvine
Journal:  Gut       Date:  1997-06       Impact factor: 23.059

8.  Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid.

Authors:  R Pamukcu; S B Hanauer; E B Chang
Journal:  Gastroenterology       Date:  1988-10       Impact factor: 22.682

9.  Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group.

Authors:  J R Green; A J Lobo; C D Holdsworth; R J Leicester; J A Gibson; G D Kerr; H J Hodgson; K J Parkins; M D Taylor
Journal:  Gastroenterology       Date:  1998-01       Impact factor: 22.682

10.  A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).

Authors:  A S Dissanayake; S C Truelove
Journal:  Gut       Date:  1973-12       Impact factor: 23.059
View more
  14 in total

1.  Balsalazide led to greater remission rates and tolerance than mesalamine in acute ulcerative colitis.

Authors:  S B Hanauer
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

2.  Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.

Authors:  Javier P Gisbert; Fernando Gomollón; José Maté; José María Pajares
Journal:  Dig Dis Sci       Date:  2002-03       Impact factor: 3.199

3.  Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.

Authors:  P Marteau; C S Probert; S Lindgren; M Gassul; T G Tan; A Dignass; R Befrits; G Midhagen; J Rademaker; M Foldager
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

Review 4.  [Consequences of galenic considerations and clinical results for therapy of ulcerative colitis].

Authors:  M Zeitz
Journal:  Med Klin (Munich)       Date:  1999-02-15

Review 5.  Advances in colonic drug delivery.

Authors:  Abdul W Basit
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.

Authors:  G Frieri; R Giacomelli; M Pimpo; G Palumbo; A Passacantando; G Pantaleoni; R Caprilli
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

7.  Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.

Authors:  W Kruis; S Schreiber; D Theuer; J W Brandes; E Schütz; S Howaldt; B Krakamp; J Hämling; H Mönnikes; I Koop; M Stolte; D Pallant; U Ewald
Journal:  Gut       Date:  2001-12       Impact factor: 23.059

8.  Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.

Authors:  W Kruis; P Fric; J Pokrotnieks; M Lukás; B Fixa; M Kascák; M A Kamm; J Weismueller; C Beglinger; M Stolte; C Wolff; J Schulze
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

9.  No dose-dependent tubulotoxicity of 5-aminosalicylic acid: a prospective study in patients with inflammatory bowel diseases.

Authors:  Carsten Dehmer; Roland Greinwald; Juergen Löffler; Wolfgang Grotz; Lothar Wolf; Hans-Burkhardt Hagmann; Werner Schneider; Wolfgang Kreisel
Journal:  Int J Colorectal Dis       Date:  2003-02-08       Impact factor: 2.571

Review 10.  Maintaining remission in ulcerative colitis--role of once daily extended-release mesalamine.

Authors:  Lilliana Oliveira; Russell D Cohen
Journal:  Drug Des Devel Ther       Date:  2011-02-27       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.